Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Lineage Cell Therapeutics, Inc. < Previous 1 2 3 Next > Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit May 06, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024 May 02, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Announces Changes to Board of Directors April 29, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 07, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM) April 30, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024 February 29, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development April 01, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering February 09, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium March 18, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering February 06, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit March 13, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting March 11, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update November 09, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury February 13, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023 November 01, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS January 16, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury December 18, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting October 24, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells October 11, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference on September 27, 2023 September 19, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration October 05, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage to Present at Baird 2023 Global Healthcare Conference and H.C. Wainwright & Co. 25th Annual Global Investment Conference August 29, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress September 13, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Cell Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update August 10, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage to Present at 2023 International Spinal Research Trust Network Meeting September 11, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Cell Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023 August 03, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Eterna Therapeutics September 06, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Cell Therapeutics Expected to Be Added to Russell 3000® Index May 22, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer July 24, 2023 From Lineage Cell Therapeutics, Inc. Via Business Wire Tickers LCTX < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.